NEW YORK (GenomeWeb) – Elucigene Diagnostics, a maker of PCR-based molecular tests, is branching further into the reproductive health and in vitro fertilization markets with assays for recurrent pregnancy loss and Y-chromosome microdeletions that can cause male infertility.

The majority of the firm's tests use capillary electrophoresis instruments from Thermo Fisher's Applied Biosystems, Chris Jones, Elucigene's sales and marketing manager, told GenomeWeb in an interview this week.